About NantHealth (NASDAQ:NH)
NantHealth, Inc. is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient's tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples. The Company also offers Nant Operating System (NantOS) and NantOS applications to healthcare providers and payors, self-insured employers and biopharmaceutical companies. It offers CLINICS, an integrated solution that includes GPS Cancer, NantOS and the NantOS applications. The CLINICS solution includes System Infrastructure, Knowledge Platform, Provider Platform and Payor Platform.
Industry, Sector and Symbol:
- Industry: Medical Software & Technology Services
- Sub-Industry: N/A
- Sector: Medical
- Symbol: NASDAQ:NH
- Previous Symbol: NYSE:NH
- CUSIP: N/A
- Web: www.nanthealth.com
- Debt-to-Equity Ratio: 0.93%
- Current Ratio: 2.38%
- Quick Ratio: 2.29%
Sales & Book Value:
- Annual Sales: $100.38 million
- Price / Sales: 3.54
- Book Value: $1.93 per share
- Price / Book: 1.70
- Trailing EPS: ($1.78)
- Net Income: ($184,100,000.00)
- Net Margins: -225.76%
- Return on Equity: -46.09%
- Return on Assets: -25.23%
- Outstanding Shares: 108,330,000
Frequently Asked Questions for NantHealth (NASDAQ:NH)
What is NantHealth's stock symbol?
NantHealth trades on the NASDAQ under the ticker symbol "NH."
How were NantHealth's earnings last quarter?
NantHealth, Inc. (NASDAQ:NH) announced its quarterly earnings data on Thursday, November, 9th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. The business earned $21.76 million during the quarter, compared to analyst estimates of $29.42 million. NantHealth had a negative return on equity of 46.09% and a negative net margin of 225.76%. The company's revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.18) earnings per share. View NantHealth's Earnings History.
Where is NantHealth's stock going? Where will NantHealth's stock price be in 2017?
4 equities research analysts have issued twelve-month price targets for NantHealth's stock. Their forecasts range from $5.00 to $13.00. On average, they expect NantHealth's stock price to reach $9.00 in the next year. View Analyst Ratings for NantHealth.
What are Wall Street analysts saying about NantHealth stock?
Here are some recent quotes from research analysts about NantHealth stock:
- 1. According to Zacks Investment Research, "Nant Health, LLC is a personalized healthcare company which enable improved patient outcomes and treatment decisions for critical illnesses. The company developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets of molecular, clinical, operational and financial data points derived from novel and traditional sources. Nant Health, LLC is based in CULVER CITY, United States. " (10/25/2017)
- 2. Cantor Fitzgerald analysts commented, "NantHealth shares are trading lower by about 18% today. The weakness is probably related to a negative article published at StatNews.com. The article claims that Dr. Patrick Soon-Shiong, Nanthealth's CEO, donated $12 million to the University of Utah. In return for the contribution, the article suggests that the University was committed to spend $10 million in "Omics Analysis". As noted above, the company disclosed on its 3Q16 conference call that the company did not recognize revenue related to 180 sequences ordered by the University of Utah. The article also tries to indicate that the company overstated the number of GPS Cancer tests it reported. It claims the orders from the University of Utah were for sequences, not for GPS Cancer tests. While the tests completed were used for preclinical research, the GPS Cancer test is a sequence by definition. Accordingly, we have no problem with the company classifying the Utah orders as GPS Cancer tests given the disclosure and the fact that it did not recognize revenue from the tests." (3/6/2017)
Who are some of NantHealth's key competitors?
Some companies that are related to NantHealth include Tabula Rasa Healthcare (TRHC), Emis Group Plc (EMIS), Castlight Health, inc. (CSLT), Craneware plc (CRW), Simulations Plus (SLP), Fluidigm Corporation (FLDM), Complete Genomics (GNOM), Medical Transcription Billing, Corp. (MTBC), Constellation Healthcare Tech (CHT) and Greenway Health (GWAY).
Who are NantHealth's key executives?
NantHealth's management team includes the folowing people:
- Patrick Soon-Shiong M.D., Chairman of the Board, Chief Executive Officer, Founder (Age 64)
- Paul A. Holt, Chief Financial Officer (Age 50)
- Michael D. Blaszyk, Independent Director (Age 64)
- Mark Burnett, Independent Director (Age 56)
- Kirk K. Calhoun, Independent Director (Age 73)
- Michael S. Sitrick, Independent Director (Age 69)
When did NantHealth IPO?
(NH) raised $91 million in an initial public offering on Thursday, June 2nd 2016. The company issued 6,500,000 shares at a price of $12.50-$15.50 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and First Analysis Securities, Canaccord Genuity and FBR were co-managers.
Who owns NantHealth stock?
NantHealth's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Highbridge Capital Management LLC (0.20%), Emerald Mutual Fund Advisers Trust (0.17%), National Planning Corp (0.11%), Dimensional Fund Advisors LP (0.07%), Bank of New York Mellon Corp (0.05%) and Schwab Charles Investment Management Inc. (0.04%). Company insiders that own NantHealth stock include Healthcare Solution Allscripts, Patrick Soon-Shiong and Ronald Allen Louks. View Institutional Ownership Trends for NantHealth.
Who sold NantHealth stock? Who is selling NantHealth stock?
Who bought NantHealth stock? Who is buying NantHealth stock?
NantHealth's stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Schwab Charles Investment Management Inc., National Planning Corp, Bank of New York Mellon Corp and Highbridge Capital Management LLC. Company insiders that have bought NantHealth stock in the last two years include Healthcare Solution Allscripts and Patrick Soon-Shiong. View Insider Buying and Selling for NantHealth.
How do I buy NantHealth stock?
Shares of NantHealth can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NantHealth's stock price today?
One share of NantHealth stock can currently be purchased for approximately $3.28.
How big of a company is NantHealth?
NantHealth has a market capitalization of $355.32 million and generates $100.38 million in revenue each year. The company earns ($184,100,000.00) in net income (profit) each year or ($1.78) on an earnings per share basis.
How can I contact NantHealth?
NantHealth's mailing address is 9920 JEFFERSON BLVD, CULVER CITY CA, 90232. The company can be reached via phone at 310-883-1300 or via email at [email protected]
MarketBeat Community Rating for NantHealth (NASDAQ NH)MarketBeat's community ratings are surveys of what our community members think about NantHealth and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for NantHealth (NASDAQ:NH) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 4 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$9.00 (174.39% upside)|
Consensus Price Target History for NantHealth (NASDAQ:NH)
Analysts' Ratings History for NantHealth (NASDAQ:NH)
(Data available from 11/19/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/17/2017||Canaccord Genuity||Lower Price Target||Buy -> Buy||$6.00 -> $5.00||N/A|
|9/28/2017||Jefferies Group LLC||Reiterated Rating||Buy||$5.00||Low|
|4/3/2017||Cantor Fitzgerald||Lower Price Target||Overweight||$15.00 -> $13.00||High|
|4/1/2017||FBR & Co||Set Price Target||Buy||$13.00||High|
|6/27/2016||First Analysis||Initiated Coverage||Overweight||$18.00||N/A|
|6/27/2016||Cowen and Company||Initiated Coverage||Outperform||$19.00||N/A|
Earnings History and Estimates Chart for NantHealth (NASDAQ:NH)
Earnings History by Quarter for NantHealth (NASDAQ NH)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2017||Q3 2017||($0.14)||($0.13)||$29.42 million||$21.76 million||View||N/A|
|8/10/2017||Q2 2017||($0.26)||($0.58)||$31.28 million||$26.23 million||View||N/A|
|5/10/2017||Q1 2017||($0.20)||($0.24)||$29.06 million||$22.51 million||View||N/A|
|3/30/2017||Q4 2016||($0.19)||($0.18)||$30.02 million||$24.10 million||View||N/A|
Earnings Estimates for NantHealth (NASDAQ:NH)
Current Year EPS Consensus Estimate: $-1.44 EPS
Next Year EPS Consensus Estimate: $-0.78 EPS
Dividend History for NantHealth (NASDAQ:NH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for NantHealth (NASDAQ NH)
Institutional Ownership Percentage: 5.31%
Insider Trades by Quarter for NantHealth (NASDAQ NH)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/6/2017||Ronald Allen Louks||COO||Sell||6,705||$3.39||$22,729.95|| |
|10/6/2017||Ronald Allen Louks||COO||Sell||26,820||$4.28||$114,789.60|| |
|6/7/2016||Healthcare Solution Allscripts||Major Shareholder||Buy||714,286||$14.00||$10,000,004.00|| |
|6/7/2016||Patrick Soon-Shiong||CEO||Buy||357,143||$14.00||$5,000,002.00|| |
Latest Headlines for NantHealth (NASDAQ NH)
|Head-To-Head Survey: NantHealth (NH) & Medical Transcription Billing, Corp. (MTBC)|
www.americanbankingnews.com - November 19 at 3:24 AM
|NantHealth Ranked Number 304 Fastest Growing Company in North America on Deloitte’s 2017 Technology Fast 500™|
finance.yahoo.com - November 18 at 7:48 AM
|NantHealth, Inc. (NH) Given New $5.00 Price Target at Canaccord Genuity|
www.americanbankingnews.com - November 17 at 7:12 PM
|Cotiviti Holdings (COTV) vs. NantHealth (NH) Head-To-Head Contrast|
www.americanbankingnews.com - November 17 at 5:06 PM
|NH Food Bank planning to distribute 18,000 turkeys this Thanksgiving|
www.msn.com - November 14 at 3:07 AM
|NH statehouse combat veterans discuss state of veterans services|
www.msn.com - November 13 at 8:52 AM
|Many happy to see snow in northern NH|
www.msn.com - November 12 at 10:55 AM
|Ohio line workers help restore power to NH residents|
www.msn.com - November 4 at 8:46 PM
|Gun Charge Dropped Against NH Mother, But Damage To Reputation Remains|
www.msn.com - November 4 at 4:55 AM
|NantHealth to Report 2017 Third-Quarter Financial Results and Host Conference Call on Thursday, November 9|
finance.yahoo.com - November 3 at 1:48 PM
|ETFs with exposure to NantHealth, Inc. : November 3, 2017|
finance.yahoo.com - November 3 at 1:48 PM
|Manhattan Beach teen dies after skateboard 'skitching' trick goes wrong|
www.latimes.com - April 11 at 10:59 AM
|Kansas Democrats Are About To Show Just How Big The Anti-Trump Wave Actually Is|
www.huffingtonpost.com - April 11 at 10:59 AM
|Joy Villa: Life has changed for the better since pro-Trump Grammys dress|
www.foxnews.com - April 10 at 10:11 AM
|5 children injured after bounce house goes airborne at South Carolina carnival|
www.foxnews.com - April 9 at 9:46 AM
|Experts Say Susan Rice Had Every Right To Request ‘Unmasking’ In Intel Reports|
www.msn.com - April 3 at 11:11 PM
|Kentucky’s Last Abortion Clinic Saved From ‘Imminent Closure’|
www.nbcnews.com - March 31 at 6:56 PM
|Professor tweets 'trying not to vomit' after passenger gives up seat to soldier|
www.usatoday.com - March 31 at 9:20 AM
|Here's proof robots are taking jobs and cutting wages|
www.foxnews.com - March 29 at 7:26 PM
|House Votes in Favor of Letting ISPs Sell Your Browsing History|
www.nbcnews.com - March 28 at 6:37 PM
|Kushner to Appear Before Senate Intel Committee on Russia|
www.nbcnews.com - March 27 at 10:08 AM
|NantHealth and Dr. Soon-Shiong Send Letters to Statnews.com Listing Errors and Corresponding Facts|
us.rd.yahoo.com - March 16 at 7:32 PM
|NantHealth Inc. (NH) Sank To A New Low On Reports Of Investigation|
www.rttnews.com - March 7 at 10:08 AM
|Cantor Fitzgerald Starts NantHealth (NH) at Overweight|
www.streetinsider.com - January 5 at 8:27 PM
|NantHealth to Raise Up $120 Mln in Notes Offering|
www.nasdaq.com - December 15 at 7:44 PM
|NantHealth Continues Global Expansion Of GPS Cancer™ By Bringing Advanced Molecular Profiling to Patients in the Middle East Through Partnership with Lunatus|
us.rd.yahoo.com - December 5 at 6:51 PM
|10:06 am Nant Health enters into an exclusive reseller agreement for GPS Cancer advanced molecular analysis with Lunatus in the Middle East|
us.rd.yahoo.com - December 5 at 6:51 PM
|NANTHEALTH, INC. Files SEC form 10-Q, Quarterly Report|
biz.yahoo.com - November 10 at 6:12 PM
|NANTHEALTH, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits|
biz.yahoo.com - November 7 at 7:03 PM
|NantHealth Inc Earnings Call scheduled for 6:00 pm ET today|
biz.yahoo.com - November 7 at 7:03 PM
|NantHealth Announces Global Expansion of GPS Cancer; Partners with Sorgente to Expand Availability of GPS Cancer™ to Italy|
www.businesswire.com - November 3 at 10:24 AM
|Cancer MoonShot 2020 Milestone: Announcing Launch Of The Nation's Largest Pediatric Brain Tumor Atlas|
www.thestreet.com - October 28 at 6:12 PM
|NantHealth Announces Immunotherapy Clinical...|
www.benzinga.com - October 26 at 6:28 PM
|NantHealth Announces Immunotherapy Clinical Trials in the Mid-Atlantic, First Whole Genomics Supercomputing Medical Reasoning Engine Helps Oncologists Make Informed Treatment ...|
www.businesswire.com - October 26 at 6:28 PM
|NANT HEALTH, LLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits|
biz.yahoo.com - August 9 at 6:42 PM
|NantHealth Inc Earnings Call scheduled for 5:00 pm ET today|
biz.yahoo.com - August 9 at 6:42 PM
NantHealth (NASDAQ NH) Chart for Sunday, November, 19, 2017